Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Next Previous
Trial Profile

An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rocapuldencel T (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ADAPT
  • Sponsors Argos Therapeutics Inc

    • Most Recent Events

    • 07 Feb 2020 Results published in the Clinical Cancer Research
    • 05 Jun 2018 Interim results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 19 Apr 2018 According to an Argos Therapeutics media release, based on the recently submitted protocol amendment focused on four co-primary endpoints of survival and review of the interim data the Company does not believe that it would achieve these endpoints if the trial were to be continued. After consulting with the principal investigators, the company has decided to discontinue the trial and has informed the FDA of its decision.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top